Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 68
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04587908 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | ||
| NCT00752011 | Phase I Study of TAS-106 in Combo With Carboplatin | ||
| NCT00152217 | Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) | ||
| NCT00150670 | Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer | ||
| NCT05335499 | A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria | ||
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen | ||
| NCT00784290 | Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | ||
| NCT02906683 | Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence | ||
| NCT00284258 | Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer | ||
| NCT02562807 | A Study of TAS-303 in Female Patients With Stress Urinary Incontinence | ||
| NCT04825431 | Mass Balance Study of [14C] TAS-205 in Healthy Volunteers | ||
| NCT00661167 | Phase II Study of ABI-007 for Gastric Cancer | ||
| NCT00142350 | A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer | ||
| NCT02246478 | A Study of TAS-205 for Duchenne Muscular Dystrophy | ||
| NCT02752048 | A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | ||
| NCT00639327 | Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer | ||
| NCT01534546 | Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection | ||
| NCT00721916 | Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer | ||
| NCT04683250 | Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities | ||
| NCT05621447 | A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects | ||
| NCT00077142 | TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | ||
| NCT00498225 | Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer | ||
| NCT00824161 | Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer | ||
| NCT00359567 | Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy | ||
| NCT02090153 | Study of S-1 Plus LV for Advanced Gastric Cancer | ||
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma | ||
| NCT02024841 | Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis | ||
| NCT04608110 | A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome | ||
| NCT01955837 | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | ||
| NCT04923529 | TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | ||
| NCT01227239 | Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting | ||
| NCT01904253 | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy | ||
| NCT00166543 | Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer | ||
| NCT05773092 | A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | ||
| NCT00152230 | A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC) | ||
| NCT04512053 | A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence | ||
| NCT00152178 | The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) | ||
| NCT00569335 | Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer | ||
| NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | ||
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | ||
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | ||
| NCT00152191 | A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC) | ||
| NCT00152243 | A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC) | ||
| NCT00202969 | Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer | ||
| NCT03605251 | Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis. | ||
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | ||
| NCT01824459 | S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients | ||
| NCT02943733 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | ||
| NCT00891332 | Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer | ||
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas |
